Skip to NavigationSkip to content

Bayer's Xarelto combo greenlighted by NICE for reducing CV events in artery disease

Published on 01/08/19 at 11:36am

NICE has awarded final appraisal recommendation to Bayer’s Xarelto (rivaroxaban) at a dosage of 2.5mg twice daily in combination with aspirin 75-100mg once daily as an option for preventing atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) who are at high risk of ischaemic events.

The UK watchdog took the decision based on results from the largest Phase 3 study undertaken into the efficacy of the drug, encompassing 27,395 patients. The findings showed that the combination reduced the risk of major adverse cardiovascular events (MACE), including cardiovascular (CV) death, stroke or myocardial infarction (MI), by 24% compared to aspirin 100mg once daily alone in patients with stable atherosclerotic vascular disease. The combo also lowered the number of MACE in patients with CAD and PAD.

The therapy will now be made available to patients on the NHS, following approval from the European Commission in April 2018.

“Cardiovascular disease remains the biggest cause of years of life lost in the UK. There have been few recent major new advances in the medical management of patients with CAD and PAD to protect them against strokes or heart attacks,” explained Dr Derek Connolly, Consultant Interventional Cardiologist and Honorary Senior Clinical Lecturer at Birmingham City Hospital, as well as a trialist on the study. “The COMPASS trial showed that adding rivaroxaban vascular dose (2.5 mg BID) to low-dose aspirin significantly reduced vascular events. The large reduction in events [such as strokes], outweighed the increase in major bleeding events seen. Conducted in more than 30 countries, including the UK, COMPASS was one of the largest ever trials of oral anti-thrombotic therapy providing robust results, overall, and particularly for key patient subgroups at high-risk of recurrent events such as those with renal dysfunction or stable ‘mild’ heart failure.

“Rivaroxaban vascular dose in combination with aspirin is the first treatment of its kind for this patient population and this recommendation from NICE provides clinicians with an important additional option for treating patients at risk of major adverse cardiac events such as CV death, stroke or MI,” he added.

Matt Fellows

Comments

This is a great inspiring article.I am pretty much pleased with your good work.You put really very helpful information. Keep it up. Keep blogging. Looking to reading your next post. cheap moving trucks

Great! It sounds good. Thanks for sharing.. fayetteville tattoo shops

The information you have posted is very useful. The sites you have referred was good. Thanks for sharing... best place to sell diabetic test strips

Thanks for the blog post buddy! Keep them coming... knee length swimwear

Great survey, I'm sure you're getting a great response. emergency locksmith

Most of the time I don’t make comments on websites, but I'd like to say that this article really forced me to do so. Really nice post! Marriage counseling

This is very educational content and written well for a change. It's nice to see that some people still understand how to write a quality post! mls listings nj

thanks for this usefull article, waiting for this article like this again. independent consultant

thanks this is good blog. notario near me

Very nice article, I enjoyed reading your post, very nice share, I want to twit this to my followers. Thanks!. iptv brasil

I can set up my new idea from this post. It gives in depth information. Thanks for this valuable information for all,.. Omni Centers

Great job for publishing such a beneficial web site. Your web log isn’t only useful but it is additionally really creative too. There tend to be not many people who can certainly write not so simple posts that artistically. Continue the nice writing Rara Avis bridal

I was surfing net and fortunately came across this site and found very interesting stuff here. Its really fun to read. I enjoyed a lot. Thanks for sharing this wonderful information. DJs in Atlanta

This blog is really great. The information here will surely be of some help to me. Thanks!. wedding photographer

Thank you for the update, very nice site.. anti-money laundering solutions

Thank you again for all the knowledge you distribute,Good post. I was very interested in the article, it's quite inspiring I should admit. I like visiting you site since I always come across interesting articles like this one.Great Job, I greatly appreciate that.Do Keep sharing! Regards, ao thanh nien tinh nguyen

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches